T1	Participants 52 128	postmenopausal women with advanced, hormone-receptor-positive breast cancer:
T2	Participants 464 518	patients with hormone-receptor-positive breast cancer.
T3	Participants 556 589	outpatient clinics and hospitals.
T4	Participants 590 744	We enrolled postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment.
T5	Participants 1437 1536	We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
T6	Participants 2492 2601	endocrine treatment in women with previously treated hormone-receptor-positive locally advanced or metastatic
